Enrollment
Platform-wide subject enrollment progress across every study under management — planned vs actual, recruitment rate, screen-failure rate, dropout rate.
Platform enrollment
7,534 / 14,220
enrolled across every active study
Recruitment rate: 135 subjects/month (trailing 6 months)
Planned
14,220
Enrolled
7,534
Screened
8,568
Screen fails
1,034
Dropouts
576
% complete
53.0%
| Study | Sponsor | Planned | Enrolled | Screened | Screen fail % | Dropout % | % complete | On track | Projected completion |
|---|---|---|---|---|---|---|---|---|---|
| ONC-002 Phase 2b | Acme Therapeutics | 120 | 78 | 113 | 31.0% | 9.0% | 65.0% | On track | 2027-05-18 |
| RARE-007 Phase 3 | Northwind Genetics | 180 | 60 | 119 | 49.6% | 11.7% | 33.3% | Behind | 2031-06-18 |
| DERM-003 Phase 2a | Lyra Skin Sciences | 120 | 96 | 121 | 20.7% | 7.3% | 80.0% | On track | 2026-11-18 |
| CV-118 Phase 3 | Helios Cardio | 8,400 | 2,100 | 2,948 | 28.8% | 11.0% | 25.0% | Behind | 2041-12-18 |
| VAX-014 Phase 2b | Stellis Vaccines | 600 | 400 | 467 | 14.3% | 9.0% | 66.7% | On track | 2027-04-18 |
| OBS-PMR-001 Observational | Veridian Pharma | 4,800 | 4,800 | 4,800 | 0.0% | 6.0% | 100.0% | On track | 2026-06-18 |